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LETTERS TO THE EDITOR
Should the anticalcification effect of epoxy
compound in vascular bioprostheses be judged
after implantation in mongrel dogs?
To the Editor:
I read with great interest the recently published article
by Ichikawa and colleagues1 on use of polyepoxy com-
pound–treated bovine jugular vein graft for reconstruc-
tion of right ventricular outflow tract in mongrel dogs. The
authors have reported that the explanted conduits main-
tained their original shape, softness, and pliability with
good coaptation of valves, without calcification or degen-
erative changes 1 year after implantation in dogs. I
congratulate them for their development of a wonderful
substitute for a valved conduit. However, clarification of
certain points would be highly appreciated.
Why have the authors chosen dogs instead of sheep for
their experimental model? Although there was mild-to-
moderate calcification of glutaraldehyde-treated porcine
aortic noncoronary cusps implanted in pulmonary circu-
lation of dogs for 5 months,2 there were no calcific
changes of glutaraldehyde cross-linked valved conduits
implanted in the systemic circulation of mongrel dogs.3
The dog is not generally considered to be a useful model
for accelerated calcification.4 Glutaraldehyde-treated
ovine collagen conduits did not calcify even by 3 years
when implanted in dogs.5 A valid conclusion with the
merit of any anticalcification technique in any bioprosthe-
ses warrants implantation of the graft in juvenile sheep.6
It is difficult to understand whether there is any chem-
ical reaction between the fresh tissue and protamine. If so,
the basic mechanism of the chemical reaction should be
mentioned. From the discussion it is quite unclear how the
authors prevent the slow release of protamine from the
graft after implantation if no covalent bonding was estab-
lished. Did protamine still remain after cross-linking in
epoxy compound? If so, how could the protamine-bonded
heparin interfere with the coagulation status of the con-
duit?
It should be kept in mind that the agents effective in
prevention of calcification of bioprosthetic valve leaflets
are not equally effective in prevention of aortic wall
calcification.7, 8 The polyepoxy compound–treated ho-
mologous aorta (calcium 5 151.51 6 27.06 mg/gm, Fig.
1) calcifies more extensively than the fresh aorta (cal-
cium 5 128.93 6 17.41 mg/gm) when implanted subcu-
taneously in weanling rats for 5 months; in addition,
coupling (covalently) of heparin is completely ineffec-
tive when considering the calcification of polyepoxy
compound–treated porcine and bovine jugular veins
and rabbit and rat aortas (personal communication with
Dr. Jyotirmay Chanda, March 2, 1997).
Every cardiovascular surgeon is aware of the complica-
tions associated with currently available valved conduits.
The need for a biocompatible valved conduit for repair of
congenital heart defects is obvious. In my opinion, one
should be cautious in planning experiments and interpret-
Fig. 1. Calcification profile of polyepoxy compound–treated homologous aorta implanted subcutaneously
in weanling rats for 5 months. Massive calcific deposits (black) along the elastin fibers of the aorta can be
noticed. (von Kossa stain; original magnification 3 50.)
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ing any positive result concerning new anticalcification
techniques in vascular bioprostheses.
Yoshikazu Goto, MD
Department of Cardiovascular Surgery
Akita University School of Medicine
Akita 010, Japan
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Reply to the Editor:
The comments by Dr. Goto were difficult for us to
understand. He noted that there was mild-to-moderate
calcification of glutaraldehyde-treated porcine aortic
cusps implanted in the pulmonary circulation of dogs,
whereas no calcific changes were observed in glutaralde-
hyde-treated valved conduits in the systemic circulation of
dogs. However, he provides no detailed explanation of
what this means. He also noted that the dog is not
generally considered to be a useful model for the study of
accelerated calcification. This sentence was quoted di-
rectly from the original article of Dr. Shemin.1 The point
of our article was the evaluation of a trileaflet biopros-
thetic valve both hemodynamically and pathologically.
Goto’s comments on this matter are also quoted in other
articles, as follows2, 3: The point of Dr. Shemin’s article
was the evaluation of a unileaflet pericardial bioprosthetic
valve both hemodynamically and pathologically in sheep
and was not for evaluation of calcification in the dog. Dr.
Shemin considered that the dog was not a useful model
for calcification according to previous investigations2, 3
that demonstrated no significant calcification despite 2
years of valve function in dogs.
We used dogs to evaluate our new conduit hemodynam-
ically and pathologically. The aim of our study was not the
evaluation of calcification. If Dr. Goto is interested in the
anticalcification effect of our bioprosthesis, we suggest he
may want to study our conduit in sheep. The details of the
graft processing are noted in “Materials and methods”
and “Discussion” of our article. References4, 5 are added
for additional clarification.
Dr. Goto explained the calcification of the polyepoxy
compound–treated aorta based on his colleague’s per-
sonal data. However, since this is not published informa-
tion, we would need more information to respond more
specifically. The laboratory data, including the number of
animals, name and concentration of the polyepoxy com-
pound, and the catalyst, reaction velocity, reaction time,
temperature, change of the pH during cross-linking, col-
lagen content of the aortic wall, cross-linking ratio of the
collagen, and the pK of the material in wet condition
would be necessary before we could comment.
Yukio Ichikawa, MD, PhD
Yasuharu Noishiki, MD, PhD
First Department of Surgery
Yokohama City University School of Medicine
3-9 Fukuura, Kanazawa-ku
Yokohama 236, Japan
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Early failure of freehand aortic stentless xenograft
valves
To the Editor:
Luciani, Bertolini, and Mazzucco1 report two cases of
supposed early (,12 months) failure with the O’Brien-
Angell stentless porcine xenograft aortic valve (now the
CryoLife-O’Brien model 300 composite aortic stentless
xenograft; CryoLife, Inc., Marietta, Ga.), which they
label as structural failures. The first patient required
reoperation for aortic valve replacement at 8 months. A
large periprosthetic dehiscence of the valve from the
host “for a length of about 1 cm at the level of the
native noncoronary cusp” had occurred. The authors
published a photograph of the explanted valve, which
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